Savara, Inc. (SVRA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.22-7.05%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Savara, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	2.69M
EPS	—	-0.16
Annual ending 2026-12-31
Revenue	—	2.3M
EPS	—	-0.635
Annual ending 2027-12-31
Revenue	—	79.68M
EPS	—	-0.39

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain borrowing capacity at $105 million	The company increased its loan capacity to $105 million.	Intact	Borrowing capacity falls below $100 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete headquarters move to Yardley, PA	It plans to move its headquarters by July 2026.	Intact	Relocation not completed by Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
FDA approval of Molbreevi for autoimmune PAP	A primary condition in Savara, Inc.'s published investment case. The stated target is FDA approval received by end of 2027.	Under Pressure	FDA approval not granted by end of 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.39

$-0.30 → $-0.39 · observed estimates

FY2027 revenue$0.08B

$0.08B → $0.08B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.30	$83,421,429	5 / 5
2026-07-25	$-0.30	$83,421,429	5 / 5
2026-07-26	$-0.30	$83,421,429	5 / 5
2026-07-27	$-0.30	$83,421,429	5 / 5
2026-07-28	$-0.30	$83,421,429	5 / 5
2026-07-29	$-0.30	$83,421,429	5 / 5
2026-07-30	$-0.29	$83,421,430	5 / 7
2026-07-31	$-0.30	$83,421,429	5 / 5
2026-08-01	$-0.30	$83,421,429	5 / 5
2026-08-02	$-0.29	$83,421,430	5 / 7
2026-08-03	$-0.30	$83,421,429	5 / 5
2026-08-04	$-0.29	$83,421,430	5 / 7
2026-08-05	$-0.29	$83,421,430	5 / 7
2026-08-06	$-0.30	$83,421,429	5 / 5
2026-08-08	$-0.30	$83,421,429	5 / 5
2026-08-09	$-0.29	$83,421,430	5 / 7
2026-08-10	$-0.30	$83,421,429	5 / 5
2026-08-12	$-0.30	$83,421,429	5 / 5
2026-08-13	$-0.29	$83,421,430	5 / 7
2026-08-14	$-0.30	$83,421,429	5 / 5
2026-08-15	$-0.30	$83,421,429	5 / 5
2026-08-16	$-0.30	$83,421,429	5 / 5
2026-08-17	$-0.30	$83,421,429	5 / 5
2026-08-18	$-0.30	$83,421,429	5 / 5
2026-08-19	$-0.30	$83,421,429	5 / 5
2026-08-20	$-0.36	$80,634,000	5 / 5
2026-08-21	$-0.36	$80,634,000	5 / 5
2026-08-22	$-0.36	$80,637,375	5 / 5
2026-08-23	$-0.36	$80,637,375	5 / 5
2026-08-24	$-0.36	$80,637,375	5 / 5
2026-08-25	$-0.36	$80,637,375	5 / 5
2026-08-26	$-0.36	$80,637,375	5 / 5
2026-08-27	$-0.36	$80,637,375	5 / 5
2026-08-28	$-0.36	$80,637,375	5 / 5
2026-08-29	$-0.36	$80,637,375	5 / 5
2026-08-30	$-0.36	$80,637,375	5 / 5
2026-08-31	$-0.36	$80,637,375	5 / 5
2026-09-01	$-0.36	$80,637,375	5 / 5
2026-09-02	$-0.36	$80,637,375	5 / 5
2026-09-03	$-0.36	$80,637,375	5 / 5
2026-09-04	$-0.36	$80,637,375	5 / 5
2026-09-05	$-0.36	$80,637,375	5 / 5
2026-09-06	$-0.36	$80,637,375	5 / 5
2026-09-07	$-0.36	$80,637,375	5 / 5
2026-09-08	$-0.36	$80,637,375	5 / 5
2026-09-09	$-0.36	$80,637,375	5 / 5
2026-09-10	$-0.36	$80,637,375	5 / 5
2026-09-11	$-0.36	$80,637,375	5 / 5
2026-09-12	$-0.36	$80,637,375	5 / 5
2026-09-13	$-0.36	$80,637,375	5 / 5
2026-09-14	$-0.36	$80,637,375	5 / 5
2026-09-15	$-0.36	$80,637,375	5 / 5
2026-09-16	$-0.36	$80,637,375	5 / 5
2026-09-17	$-0.36	$80,637,375	5 / 5
2026-09-18	$-0.36	$80,637,375	5 / 5
2026-09-19	$-0.36	$80,637,375	5 / 5
2026-09-20	$-0.36	$80,637,375	5 / 5
2026-09-21	$-0.36	$80,637,375	5 / 5
2026-09-22	$-0.36	$80,637,375	5 / 5
2026-09-23	$-0.36	$80,637,375	5 / 5
2026-09-24	$-0.36	$80,637,375	5 / 5
2026-09-25	$-0.36	$80,637,375	5 / 5
2026-09-26	$-0.36	$80,637,375	5 / 5
2026-09-27	$-0.36	$80,637,375	5 / 5
2026-09-28	$-0.36	$80,637,375	5 / 5
2026-09-29	$-0.36	$80,637,375	5 / 5
2026-09-30	$-0.36	$80,637,375	5 / 5
2026-10-01	$-0.36	$80,637,375	5 / 5
2026-10-02	$-0.36	$80,637,375	5 / 5
2026-10-03	$-0.36	$80,637,375	5 / 5
2026-10-04	$-0.36	$80,637,375	5 / 5
2026-10-05	$-0.36	$80,637,375	5 / 5
2026-10-06	$-0.36	$80,637,375	5 / 5
2026-10-07	$-0.36	$80,637,375	5 / 5
2026-10-08	$-0.39	$79,677,667	5 / 6
2026-10-09	$-0.39	$79,677,667	5 / 6
2026-10-10	$-0.39	$79,677,667	5 / 6
2026-10-11	$-0.39	$79,677,667	6 / 6
2026-10-12	$-0.39	$79,677,667	6 / 6
2026-10-13	$-0.39	$79,677,667	6 / 6
2026-10-14	$-0.39	$79,677,667	6 / 6
2026-10-15	$-0.39	$79,677,667	6 / 6
2026-10-16	$-0.39	$79,677,667	6 / 6
2026-10-17	$-0.39	$79,677,667	6 / 6
2026-10-18	$-0.39	$79,677,667	6 / 6
2026-10-19	$-0.39	$79,677,667	6 / 6
2026-10-20	$-0.39	$79,677,667	6 / 6
2026-10-21	$-0.39	$79,677,667	6 / 6
2026-10-22	$-0.39	$79,677,667	6 / 6
2026-10-23	$-0.39	$79,677,667	6 / 6
2026-10-24	$-0.39	$79,677,667	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	8	0	0
2026-10-01	9	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 7

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain borrowing capacity at $105 millionDirect metric needs a verified mapping
Complete headquarters move to Yardley, PADirect metric needs a verified mapping
FDA approval of Molbreevi for autoimmune PAPPublished status: Under Pressure

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-39.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Savara, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making healthcare growth story, not an established earnings compounder. The long-term thesis is in a watch state, with low confidence because recent financial performance is weak relative to its industry cohort.

What's priced into Savara, Inc.

The evidence snapshot provides no valuation or market-expectations data, so whether SVRA is cheap, fair, or expensive cannot be assessed. It also does not show what investors already assume about future growth or profitability.

What the fundamentals likely do

Near-term fundamentals face pressure: operating and net losses widened from 2025-Q3 to 2026-Q2, and the evidence flags an elevated risk of another earnings miss. The $105 million term loan is intended to support growth and operations, but current results show limited progress toward profitability; the recent FDA approval is a positive event, though its financial effect is not provided.

What Savara, Inc. hinges on

Over the next few quarters, the thesis depends on execution and whether losses begin to improve without guidance cuts. A weakening jobs trend could add pressure through recession concerns, while continued strength among Healthcare bellwethers such as VRTX, REGN, and MRNA could support sector momentum. The effects of the leadership change and the new office lease are not yet established.